Haematopoietic stem cell donation represents a unique chance for curing patients affected with onchohaematologic and inherited diseases.If a related donor is unavailable a unrelated donor must be used. For both categories an accurate physical and laboratory examination is mandatory to establish the eligibility to bone marrow or peripheral blood stem cell collection since side effects related to donation may occur. To ensure high standards of safety and satisfaction of unrelated stem cells donors dedicated guidelines are available. On the other hand, there is no unambiguous guidance on the management of the related donor and published data on donation and long term follow-up are scarce.
The study, for the retrospective part, aims to report the experience in family and registry donor management at Transfusion Service from 2016 to 2022 (enrollment, stem cell donation, 30-day follow-up) and, for the prospective part, to continue monitoring on donors who will be enrolled in the next five years (2023 to 2028).
Study Type
OBSERVATIONAL
Enrollment
400
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy
RECRUITINGsafety of stem cell donation
The proportion of overall serious adverse reactions/events (number of patient-reactions out of the total number of patients)
Time frame: From enrollment to 30 days after stem cell donation
peripheral stem cells analysis
Measurement of blood counts and CD34+ cells pre-donation and in the collected product
Time frame: From enrollment to 30 days after stem cell donation
lymphocyte analysis
Cytofluorimetric analysis of lymphocyte subpopulations (CD4, CD8, CD4/8 ratio) at donor enrollment
Time frame: From enrollment to 30 days after stem cell donation
CBC analysis
CBC examination at different measurement times
Time frame: From enrollment to 30 days after stem cell donation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.